<DOC>
	<DOCNO>NCT01540669</DOCNO>
	<brief_summary>The aim study test effect polydextrose whole gut transit time gastrointestinal symptom dose-responsive manner .</brief_summary>
	<brief_title>Dose-Responsive Effect Polydextrose Whole Gut Transit Time</brief_title>
	<detailed_description>Given promising , yet largely unsubstantiated , benefit fiber supplementation , particularly polydextrose , symptoms functional constipation , objective clinical trial evaluate safety effectiveness 2-week supplementation proprietary polydextrose fiber product , dose-ranging fashion , whole gut transit time gastrointestinal symptom adult functional constipation .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Age 18 70 year Body mass index 18.5 29.9 kg/m2 ( encompass normal weight overweight ) Meets Rome III criterion functional constipation follow : ( Criteria fulfil last 3 month symptom onset least 6 month prior diagnosis ) : Must meet 2 follow criterion : Straining least 25 % defecation Lumpy hard stool least 25 % defecation Sensation incomplete evacuation least 25 % defecation Sensation anorectal obstruction/blockage least 25 % defecation Manual maneuver facilitate least 25 % defecation ( e.g. , digital evacuation , support pelvic floor ) Fewer three defecation per week Loose stool rarely present without use laxative Insufficient criterion irritable bowel syndrome Ability participant ( investigator 's opinion ) comprehend full nature purpose study include possible risk side effect Consent study willing comply study product method Willingness maintain stable diet throughout study Consistent use dose chronic medication , , past 30 day Major gastrointestinal complication ( e.g . Crohn‟s disease , colitis , celiac disease ) Febrile diverticulitis within 1 year screen Pelvic floor dysfunction Prior abdominal surgery opinion investigator may present risk subject confound study result Prior abdominal surgery follow type : gastric bypass , lap band , colectomy , removal gall bladder Clinically significant underlying systemic illness may preclude subject‟s ability complete trial may confound study outcomes Any clinically relevant abnormality physical examination laboratory variable entry study Daily consumption probiotic , prebiotics , ferment milk , and/or yogurt within 2 week screen Laxative , fiber supplement , constipation medication ( e.g . prokinetic drug ) use within 2 week screen Antibiotic use within 1 month enrollment Regular use drug dietary supplement know cause constipation ( e.g . iron , opioids , sucralfate , misoprostol , 5HT # antagonist , antacid magnesium aluminum , diarrhea medication ) Anticipated major dietary exercise change study period Known allergy substance study product Pregnant lactate female , pregnancy plan study period Eating disorder History alcohol , drug , medication abuse Participation another study investigational product within 3 month screen Investigator believe participant may uncooperative and/or noncompliant therefore participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>constipation</keyword>
	<keyword>functional constipation</keyword>
	<keyword>polydextrose</keyword>
	<keyword>whole gut transit time</keyword>
</DOC>